Founder Intelligence

Jacob Donoghue MD

Advancing technology at Beacon Biosignals requires rigorous software engineering, disciplined execution, and solving real operational bottlenecks for enterprise users.

Role
CEO & Co-Founder
Country
United States
Company founded
2019
Status
Active

Known for

Beacon Biosignals provides enterprise-grade artificial intelligence solutions, delivering specialized Beacon Biosignals Platform technology designed to optimize…

Ecosystem Connection Map

How this founder connects across companies, products, industries, and research on Brel.

Overview

Structured founder intelligence — role, focus, and why this person matters in the AI ecosystem.

Jacob Donoghue MD is a technology executive based in United States, currently serving as CEO & Co-Founder at Beacon Biosignals.

Why it matters

In the modern technology ecosystem, Jacob Donoghue MD's leadership at Beacon Biosignals exemplifies the operational stewardship needed to translate engineering innovations into dependable commercial software.

Editorial insight

Donoghue combines Harvard Medical School and MIT neuroscience training with CEO leadership at Beacon, advancing AI-driven neurotechnology from academic research into biopharma and clinical sleep diagnostics.

Career & Timeline

Verified career context from this founder profile.

Career & Leadership

Throughout their career in technology, Jacob Donoghue MD has directed software development, product architecture, and commercial scaling at Beacon Biosignals.

Industry & Technical Contributions

At Beacon Biosignals, Jacob Donoghue MD's leadership has supported the design, deployment, and adoption of mission-critical software systems tailored for enterprise users.

  • Company founded 2019 · founded Beacon Biosignals was founded in 2019 per the company profile source on file. Source
  • Acquisition 2025 · acquisition April 21, 2025: Beacon completed acquisition of CleveMed, expanding home sleep testing capabilities. Source
  • Funding 2026 · funding April 6, 2026: Beacon announced Series B extension bringing round total to $97 million and cumulative funding to over $132 million. Source

Companies

Organizations connected to this founder in the Brel graph.

Products

Products and platforms linked to this founder or their organization.

  • Beacon Platform Biotechnology

    Explore Beacon Platform by Beacon Biosignals. Verified AI product intelligence covering core capabilities, Healthcare use cases, technical architecture,…

    View product

Technologies & Expertise

Verified technology terms linked to this founder.

Industries & Use Cases

Sectors and use cases connected to this founder profile.

Funding

Verified funding disclosures from the connected company profile.

  • April 6, 2026: Beacon announced Series B extension bringing round total to $97 million and cumulative funding to over $132 million.

Latest Developments

Recent milestones from the connected organization.

  • April 6, 2026: Beacon announced Series B extension bringing round total to $97 million and cumulative funding to over $132 million. Latest
  • Leadership 2019 · leadership Source

Related Intelligence

Reports and insights editorially linked to this founder.

FAQ

Answers restated from verified fields on this profile.

Who is Jacob Donoghue MD?

Jacob Donoghue MD is a technology leader and entrepreneur currently serving as CEO & Co-Founder at Beacon Biosignals.

What company is Jacob Donoghue MD associated with?

Jacob Donoghue MD is associated with Beacon Biosignals, leading product and technical initiatives.

Where is Jacob Donoghue MD based?

Jacob Donoghue MD is based in United States.

What are Jacob Donoghue MD's key contributions to the industry?

Jacob Donoghue MD focuses on scalable software architecture, enterprise product development, and applied artificial intelligence leadership at Beacon Biosignals.

Sources & Verification

Verified
Last reviewed Aug 2026

Primary sources

In this profile